Better prioritization may speed approval of adjuvant therapies in breast cancer.
Tuma
Rabiya S
RS
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D017277:Drug Approval; D005260:Female; D006801:Humans; D008495:Medical Oncology; D016032:Randomized Controlled Trials as Topic / Q000592:standards / Q000639:trends; D012955:Societies, Medical; D036302:Therapeutic Human Experimentation; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents